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The signaling molecule nitric oxide (NO) is of crucial
importance for smooth muscle cell (SMC) function and
exerts numerous, sometimes opposing effects on vascular
proliferative diseases, such as atherosclerosis and resteno-
sis. Under physiological conditions many effects of NO
are mediated via the cyclic guanosine-3',5'-monophos-
phate (cGMP)/cGMP-dependent protein kinase type I
(cGKI) pathway. In the cardiovascular system protective
effects of NO signaling have been generally attributed to
cGMP/cGKI. In contrast, novel genetic evidence from the
analysis of atherosclerosis-prone mice indicated that
endogenous cGKI accelerated plaque growth and, thus,
was pro-atherogenic. However, in restenosis after intra-
arterial interventions, such as balloon angioplasty or stent
placement the mediator(s) of NO signals, in particular the
role of endogenous SMC cGKI is unclear. Towards a better
understanding of cGKI and its function in restenosis the
Cre-loxP site-specific recombination system was used to
generate conditional cardiac and SMC cGKI knockout
mice. To test whether the lack of cGKI in SMCs affects the
injury-induced vascular remodelling conditional mutants
and control mice were analysed by morphometry and
immunohistochemistry at different time points after
injury, in a normolipidemic situation as well as on an
apolipoprotein E-deficient genetic background. In addi-
tion, by continuous administration of sildenafil the
cGMP/cGKI pathway was chronically activated in wild
type mice subjected to the injury.
Taken together, the analysis of different mouse models of
vascular proliferative diseases suggests a context-specific
relevance of the cGMP/cGKI pathway for atherosclerosis
and restenosis.
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